177 related articles for article (PubMed ID: 32514049)
21. In vivo assessment of tumor heterogeneity in WHO 2016 glioma grades using diffusion kurtosis imaging: Diagnostic performance and improvement of feasibility in routine clinical practice.
Hempel JM; Schittenhelm J; Bisdas S; Brendle C; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Klose U
J Neuroradiol; 2018 Feb; 45(1):32-40. PubMed ID: 28865921
[TBL] [Abstract][Full Text] [Related]
22. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
23. Comparison of unsupervised classification methods for brain tumor segmentation using multi-parametric MRI.
Sauwen N; Acou M; Van Cauter S; Sima DM; Veraart J; Maes F; Himmelreich U; Achten E; Van Huffel S
Neuroimage Clin; 2016; 12():753-764. PubMed ID: 27812502
[TBL] [Abstract][Full Text] [Related]
24. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
[TBL] [Abstract][Full Text] [Related]
25. Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas.
Carceller F; Jerome NP; Fowkes LA; Khabra K; Mackinnon A; Bautista F; Marshall LV; Vaidya S; Mandeville H; Morgan V; Leach MO; Koh DM
Pediatr Hematol Oncol; 2019 Mar; 36(2):103-112. PubMed ID: 30978130
[No Abstract] [Full Text] [Related]
26. Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation.
Ciezka M; Acosta M; Herranz C; Canals JM; Pumarola M; Candiota AP; Arús C
J Neurooncol; 2016 Aug; 129(1):67-76. PubMed ID: 27324642
[TBL] [Abstract][Full Text] [Related]
27. VERDICT MRI for radiation treatment response assessment in neuroendocrine tumors.
Lundholm L; Montelius M; Jalnefjord O; Forssell-Aronsson E; Ljungberg M
NMR Biomed; 2022 Jun; 35(6):e4680. PubMed ID: 34957637
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of diffuse glioma grade and proliferation activity by different diffusion-weighted-imaging models including diffusion kurtosis imaging (DKI) and mean apparent propagator (MAP) MRI.
Xie SH; Lang R; Li B; Zhao H; Wang P; He JL; Ma XY; Wu Q; Wang SY; Zhang HP; Gao Y; Wu JL
Neuroradiology; 2023 Jan; 65(1):55-64. PubMed ID: 35835879
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma.
Hernandez-Lain A; Hilario A; Sepulveda JM; Cantero D; Ramos A; Perez-Nuñez A
Neurology; 2016 Jul; 87(1):114-5. PubMed ID: 27251883
[No Abstract] [Full Text] [Related]
30. Imaging temozolomide-induced changes in the myeloid glioma microenvironment.
Foray C; Valtorta S; Barca C; Winkeler A; Roll W; Müther M; Wagner S; Gardner ML; Hermann S; Schäfers M; Grauer OM; Moresco RM; Zinnhardt B; Jacobs AH
Theranostics; 2021; 11(5):2020-2033. PubMed ID: 33500706
[No Abstract] [Full Text] [Related]
31. The relationship between diffusion heterogeneity and microstructural changes in high-grade gliomas using Monte Carlo simulations.
Lee CY; Bennett KM; Debbins JP; Choi IY; Lee P
Magn Reson Imaging; 2022 Jan; 85():108-120. PubMed ID: 34653578
[TBL] [Abstract][Full Text] [Related]
32. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Dhermain F
Chin J Cancer; 2014 Jan; 33(1):16-24. PubMed ID: 24384237
[TBL] [Abstract][Full Text] [Related]
33. Preoperative grading of supratentorial gliomas using high or standard b-value diffusion-weighted MR imaging at 3T.
Cihangiroglu MM; Ozturk-Isik E; Firat Z; Kilickesmez O; Ulug AM; Ture U
Diagn Interv Imaging; 2017 Mar; 98(3):261-268. PubMed ID: 28038915
[TBL] [Abstract][Full Text] [Related]
34. Earlier detection of tumor treatment response using magnetic resonance diffusion imaging with oscillating gradients.
Colvin DC; Loveless ME; Does MD; Yue Z; Yankeelov TE; Gore JC
Magn Reson Imaging; 2011 Apr; 29(3):315-23. PubMed ID: 21190804
[TBL] [Abstract][Full Text] [Related]
35. Apparent diffusion coefficient histograms may predict low-grade glioma subtype.
Tozer DJ; Jäger HR; Danchaivijitr N; Benton CE; Tofts PS; Rees JH; Waldman AD
NMR Biomed; 2007 Feb; 20(1):49-57. PubMed ID: 16986106
[TBL] [Abstract][Full Text] [Related]
36. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
[TBL] [Abstract][Full Text] [Related]
37. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.
Subramani E; Radoul M; Najac C; Batsios G; Molloy AR; Hong D; Gillespie AM; Santos RD; Viswanath P; Costello JF; Pieper RO; Ronen SM
Cancer Res; 2020 Nov; 80(22):5098-5108. PubMed ID: 32958546
[TBL] [Abstract][Full Text] [Related]
38. MRI based texture analysis to classify low grade gliomas into astrocytoma and 1p/19q codeleted oligodendroglioma.
Zhang S; Chiang GC; Magge RS; Fine HA; Ramakrishna R; Chang EW; Pulisetty T; Wang Y; Zhu W; Kovanlikaya I
Magn Reson Imaging; 2019 Apr; 57():254-258. PubMed ID: 30465868
[TBL] [Abstract][Full Text] [Related]
39. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
40. Tissue-type mapping of gliomas.
Raschke F; Barrick TR; Jones TL; Yang G; Ye X; Howe FA
Neuroimage Clin; 2019; 21():101648. PubMed ID: 30630760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
